T
OTAL TAU (T-TAU), TAU PHOSphorylated at threonine 181 (p-tau 181 ), and ␤-amyloid 1-42 peptide (A␤42) in cerebrospinal fluid (CSF) are well-established Alzheimer disease (AD) biomarkers. 1 The combination of increased T-tau or p-tau 181 and decreased A␤42 is strongly associated with a diagnosis of AD even at its earliest stages. 1, 2 For this reason, investigators have examined whether CSF analytes have prognostic value with respect to progression to AD dementia among patients with mild cognitive impairment (MCI). 3, 4 These studies found that patients with MCI who had dual CSF abnormalities (ie, increased T-tau or p-tau 181 and decreased A␤42) are at increased risk of progressing to AD dementia compared with those patients with normal CSF.
A question that has not received much attention is that of the longitudinal course and outcome of patients with MCI who have abnormalities in tau or A␤42 but not both. To our knowledge, only 2 studies 5, 6 have examined differences in cognitive performance and clinical attributes among patients with MCI stratified by patterns of CSF alterations. Of note, both studies were performed using cross-sectional data and thus could not provide information regarding the prospective course or long-term outcome of these MCI CSF profiles. In this study, we address this knowledge gap by investigating longitudinal course (decline on measures of global cognition and disease progression) and outcome (risk of conversion to AD dementia) within a well-characterized group of patients with amnestic MCI, subtyped by their pattern of CSF abnormality.
METHODS

STUDY PARTICIPANTS
The analyses presented here are based on data from the Alzheimer's Disease Neuroimaging Initiative (ADNI; http: //adni.loni.ucla.edu/). The ADNI was launched in 2003 by the National Institute on Aging and other entities (see the "Acknowledgments" section) as a 5-year public-private partnership. Enrollment target was 800 participants-200 healthy control individuals, 400 patients with amnestic MCI, and 200 patients with mild AD-at 58 sites in the United States and Canada. Participants were evaluated at 6-month intervals for 2 (mild AD) or 3 (controls and MCI) years. Further details regarding ADNI, including participant selection procedures and complete study protocol, have been presented elsewhere 1 and can be found online at http://www.alzheimers.org/clinicaltrials/fullrec.asp ?PrimaryKey=208.
The present analyses included all 195 patients with amnestic MCI who had valid test results for CSF T-tau, A␤42, and p-tau 181 when data download occurred between September 1 and 30, 2009. Diagnosis of amnestic MCI required subjective memory difficulties, objective memory difficulties (established using education-specific cut scores on the delayed recall of story A measure from the Logical Memory Test 7 ), normal activities of daily living, Clinical Dementia Rating Scale (CDR) Global score of 0.5, and Mini-Mental State Examination scores of 24 or higher. Informed consent was obtained from study participants and their families, and the study was approved by the local institutional review board at each participating site.
CSF PROCEDURE AND APOLIPOPROTEIN E GENOTYPING
Full details of the collection and analysis of CSF samples in ADNI have been provided elsewhere. 1 Briefly, lumbar puncture was performed in the morning after an overnight fast. Aliquots (0.5 mL) were subsequently prepared from the CSF samples and stored in bar code-labeled polypropylene vials at −80°C. The T-tau, A␤42, and p-tau 181 were assayed from these aliquots using the multiplex xMAP Luminex platform (Luminex Corp, Austin, Texas) with immunoassay kit-based reagents (INNO-BIA AlzBio3; Innogenetics, Ghent, Belgium; for research use only). Participants also provided EDTA blood samples, on which APOE genotyping was performed using TaqMan assays, as previously described.
1
CLINICAL ASSESSMENT
Participants completed the following neuropsychological measures: story A from the Logical Memory Test, 7 Category Fluency Test (animals and vegetables), 8 the Boston Naming Test, 9 Clock Drawing Test, 10 Digit Span Test, 11 Digit Symbol Substitution Test, 11 Trail Making Test (parts A and B), 12 and the Rey Auditory Verbal Learning Test. 13 Taken together, these tests assess the domains of episodic memory, attention, language, executive function, processing speed, and spatial abilities. For our analyses, participants' scores on the neuropsychological measures were transformed to z scores using group means and standard deviations at baseline. Next, these z scores were averaged, yielding a composite cognitive measure. Such summary measures reduce floor and ceiling effects and other sources of measurement error. Participants also completed the CDR, the Mini-Mental State Examination, the Neuropsychiatry Inventory Questionnaire, 14 and the Geriatric Depression Scale.
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STATISTICAL ANALYSES
Abnormality on CSF biomarkers was defined using cutoffs (T-tau Ͼ93 pg/mL, A␤42 Ͻ192 pg/mL, and p-tau 181 Ͼ23 pg/mL) previously shown to maximally distinguish patients with AD from healthy controls within the ADNI cohort. 1 Next, we created CSF profiles among the patients with MCI by crosstabulating abnormalities in T-tau and A␤42 based on these cutoff thresholds to obtain 4 groups of study participants: (1) those who had normal T-tau and normal A␤42 (normal-TtauA␤42), (2) those who had normal T-tau but abnormal A␤42 (abnormal-A␤42), (3) those who had abnormal T-tau but normal A␤42 (abnormal-T-tau), and (4) those who had abnormal T-tau and abnormal A␤42 (abnormal-T-tauA␤42). We also created a second set of CSF profiles by crosstabulating abnormalities in p-tau 181 and A␤42 to obtain an analogous grouping of study participants.
To investigate potential differences in longitudinal course related to CSF profile, we fitted 2 random coefficient regressions. 16 The first regression modeled rate of change in the composite cognitive measure, whereas the second regression modeled rate of change in the CDR sum of boxes (CDR-SB) subscale. The CDR-SB is a sum of scores for the 6 CDR domains and has proven particularly useful in tracking disease progression and functional impairment over time. 17 Both regression models were adjusted for APOE ε4 because its distribution significantly varied across groups ( Table 1 and Table 2 ). Cox proportional hazards models, 16 adjusted for APOE ε4, were fitted to determine whether risk of converting to AD dementia differed across CSF profiles. Participants were censored at their last visit or the visit at which they were diagnosed as having AD dementia. Analyses were performed using SAS statistical software, version 9.2 (SAS Institute Inc, Cary, North Carolina), or SPSS statistical software, version 16 (SPSS Inc, Chicago, Illinois).
RESULTS
GROUP CHARACTERISTICS AT BASELINE
The distribution of the CSF profiles formed by crosstabulating T-tau and A␤42 findings was as follows: (1) normal-T-tauA␤42 (n=47), (2) abnormal-A␤42 (n=61), (3) abnormal-T-tau (n = 3), and (4) abnormal-TtauA␤42 (n = 84). For the CSF profiles involving ptau 181 and A␤42, the distribution was as follows: (1) normal-p-tau 181 A␤42 (n=39), (2) abnormal-A␤42 (n=19), (3) abnormal-p-tau 181 (n = 11), and (4) abnormal-ptau 181 A␤42 (n=126). Tables 1 and 2 give the results of group comparisons regarding baseline characteristics. The 4 groups formed by cross-tabulating T-tau and A␤42 were statistically indistinguishable on all measures except for the proportion of persons possessing 1 or more copies of the APOE ε4 allele and scores on the composite cognitive measure. Patients with MCI with abnormal-A␤42 or abnormal-T-tauA␤42 were more likely to possess 1 or more copies of the APOE ε4 allele and to have lower scores on the composite cognitive measure compared with those who had normal-T-tau/A␤42 or abnormal-T-tau. The 4 groups formed by cross-tabulating p-tau 181 and A␤42 differed statistically only on these same variables, with a similar pattern of group separation. 
EFFECT OF CSF PROFILE ON PARTICIPANTS' LONGITUDINAL COURSE: COMPOSITE COGNITIVE MEASURE
The abnormal-A␤42 (␤=−0.06, SE=0.02, P=.01) and abnormal-T-tauA␤42 (␤ = −0.11; SE = 0.02; P = .01) groups experienced significantly faster rates of decline in composite cognition relative to the normal-T-tauA␤42 group. In contrast, the rate of decline within the abnormal-Ttau group (␤=−0.02; SE=0.07; P=.73) did not differ from that of the normal-T-tauA␤42 group. These findings are shown in Figure 1 . As is evident, patients in the abnormal-T-tauA␤42 group experienced the fastest decline in cognitive function among all groups. Similar results (not shown) were obtained within the groups formed by ptau 181 and A␤42. Abbreviations: A␤42, ␤-amyloid 1-42; APOE, apolipoprotein E; CDR, Clinical Dementia Rating Scale; GDS, Geriatric Depression Scale; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; NA, not applicable; NPI-Q, Neuropsychiatric Inventory Questionnaire; T-tau, total tau.
a Normal-T-tauA␤42 indicates patients with MCI who have normal T-tau and normal A␤42; abnormal-A␤42, patients with MCI who have normal T-tau but abnormal A␤42; abnormal-T-tau, patients with MCI who have abnormal T-tau but normal A␤42; and abnormal-T-tauA␤42, patients with MCI who have abnormal T-tau and abnormal A␤42.
b APOE ε4 positive indicates possession of 1 or more copies of the APOE ε4 allele. 
CONVERSION TO AD DEMENTIA DURING THE STUDY PERIOD
Of the 195 patients with MCI included in this study, 76 (39.0%) converted to AD dementia within a median follow-up time of 23 months (range,6-39 months). For the 4 groups formed by cross-tabulating T-tau and A␤42, the distribution of conversions to AD dementia was as follows: (1) 
RISK OF CONVERTING TO AD DEMENTIA AS A FUNCTION OF CSF PROFILE
With the normal-T-tauA␤42 group as the reference, the risk of converting to AD dementia was significantly higher in the abnormal-A␤42 and abnormal- 18 Survival plots for this analysis are shown in Figure 3 . Of note, the reported quasi-complete separation did not emerge when the analysis was repeated among the groups formed by the cross-tabulation of p-tau 181 and A␤42.
ANALYSES OF DATA RESTRICTED TO 18 MONTHS OF FOLLOW-UP
Because the typical length of AD clinical trials is 18 months, we repeated the Cox proportional hazards models using only the data acquired within the first 18 months of follow-up to determine whether the foregoing pattern of findings would emerge. There were 55 conversions to AD dementia during this period. Because 76 conversions occurred during the total length of follow-up (maximum of 39 months), most conversions evidently occurred during the initial 18-month period. Within the 4 T-tauA␤42 groups, the distribution of conversions was as follows: (1) The Cox regression analyses showed that the risk for converting to AD dementia was significantly greater for the abnormal-A␤42 and abnormal-T-tauA␤42 groups (HR, 2.52; 95% CI, 1.03-6.13; P=.04; and HR, 2.46; 95% CI, 1.02-5.96; P=.05; respectively) compared with the normal-T-tauA␤42 group. As with the original analysis, the hazard for the abnormal-T-tau group (␤=−12.31) was statistically untestable. These findings were replicated overall within the 4 groups defined by the crosstabulation of p-tau 181 and A␤42 (data not shown). Thus, the 18-month results are consistent with the findings based on data collected during the entire study period.
ANCILLARY ANALYSES: CSF BIOMARKER CONCENTRATIONS AND LONGITUDINAL COURSE AND OUTCOME
Because prior MCI investigations of the association between CSF biomarkers and prospective course and out- come have primarily analyzed biomarker concentrations 3, 4, 19, 20 (as opposed to profiles, as we have done here), we repeated our analyses using biomarker concentrations. Briefly, we fit (1) a random-effects regression that simultaneously examined the effects of A␤42, T-tau, ptau 181 , the ratio of t-tau to A␤42 (T-tau/A␤42), and the ratio of p-tau 181 to A␤42 (p-tau 181 /A␤42) on rate of change on the composite cognitive measure, (2) another randomeffects regression that simultaneously examined the effects of these CSF biomarkers on rate of change on the CDR-SB, and finally (3) a Cox proportional hazards model that simultaneously examined the effects of these CSF biomarkers on risk of converting to AD dementia. All analyses adjusted for APOE ε4. In summary, only A␤42 (P=.009) and p-tau 181 (P=.03) were associated with rate of cognitive decline, only A␤42 (P = .001) was associated with rate of increase in CDR-SB scores, and only A␤42 (P =.001) was associated with risk of conversion to AD dementia. These results support our original findings concerning the centrality of A␤42 abnormalities with respect to cognitive decline, disease progression, and conversion to AD dementia in this cohort.
COMMENT
In this study, we examined the relationship of 2 sets of CSF profiles to 3 outcome measures: (1) rate of decline on a composite cognitive measure, (2) rate of disease progression (based on change in CDR-SB scores), and (3) risk of converting to AD dementia. Within the 4 groups formed by cross-tabulating T-tau and A␤42, we found that, compared with patients who have normal-TtauA␤42, (1) those with abnormal-A␤42 or abnormal-T-tauA␤42 had a steeper rate of decline on the composite cognitive measure, whereas those with abnormal-Ttau did not; (2) those with abnormal-A␤42 or abnormal-T-tauA␤42 experienced a significant worsening of disease, whereas those with abnormal-T-tau did not; and (3) those with abnormal-A␤42 or abnormal-T-tauA␤42 were at increased risk of converting to AD dementia, whereas those with abnormal-T-tau were not any more likely to experience conversion to AD dementia. In summary, these analyses showed that patients with MCI who had abnormal-A␤42, whether the T-tau was normal or not, had worse outcomes, whereas patients with MCI who had normal-A␤42, even when the T-tau was abnormal, had comparatively better outcomes. Similar findings were made when the analyses were repeated within the 4 groups formed by p-tau 181 and A␤42.
Our manner of creating the CSF subgroups examined in this study is noteworthy. Recent studies 3, 21 have suggested that biomarker ratios may be more sensitive to incipient AD compared with absolute biomarker levels. However, by virtue of being ratios, such measures obscure an important distinction between individuals who have normaltau but abnormal-A␤42 and those who have abnormaltau but normal-A␤42. For instance, exploratory analyses in this study found that the abnormal-T-tau group (mean 
/ A␤42 ratio (P=.77). In contrast to the apparent similarity of these 2 classes of MCI patients (ie, those with only abnormal-tau and those with only abnormal-A␤42) on the biomarker ratios, our analyses showed that their prospective course and outcome are different. 22 The overall finding from this study is that, of the 2 types of CSF abnormalities commonly observed in patients with MCI (ie, increased T-tau or p-tau 181 and decreased A␤42), abnormally low A␤42 appears to be most closely associated with cognitive decline, disease progression, and risk of conversion to AD dementia. This finding is consistent with prior investigations 6, 19, 23 that found that CSF A␤42 concentrations are predictive of future conversion to AD dementia among patients with MCI, whereas tau concentrations are not. Because abnormally low CSF A␤42 is presumed to be due to ␤-amyloid aggregation in the brain, 24 our findings are in accordance with the amyloid cascade hypothesis, which, in brief, argues that deposition of ␤-amyloid in the brain is an early event in AD pathogenesis. 25 However, we note that the tenets of the amyloid cascade hypothesis remain controversial. 26 Indeed, some evidence exists that elevated CSF T-tau or p-tau 181 , but not decreased A␤42, predict progression from MCI to AD dementia. 20 The reasons for these seemingly conflicting findings are not fully understood and suggest the need for continued investigation of these important questions. 2, 27 In addition, although our findings suggest that A␤42 abnormities are prominently associated with risk of progression to dementia, all models tested in this study consistently demonstrated that individuals with combined tau and A␤42 abnormalities had the worst outcomes. 3 This study contributes to the ongoing attempts to identify subgroups of patients with MCI at increased risk of progressing to AD dementia 3, 4 by demonstrating that patients with MCI who have abnormal A␤42 have an elevated risk of cognitive decline and eventual conversion to AD dementia even when the tau is normal. The ability to detect incipient dementia in patients with MCI has obvious implications for clinical trials. One reason why MCI trials have experienced little success to date is the relatively slow disease progression among some study enrollees, which affects the ability of these trials to test key hypotheses. Enrolling patients with MCI who are more likely to convert to AD dementia could shorten the time to attain the primary milestones, reduce the sample size needed for adequate power, and increase the ability to detect treatment effects. 28 In addition, the finding that abnormal A␤42 is comparatively more strongly associated with progressive decline and eventual conversion to AD suggests that the ability to abrogate the accumulation of A␤ peptides in the brain and/or restore A␤42 in CSF might be a valid outcome for MCI drug trials, especially those in the phase 2 (proof-of-concept) stage. 29 An important caveat is that, in this ADNI cohort, individuals with abnormal A␤42 were also more likely to possess 1 or more copies of the APOE ε4 allele and there is some evidence that APOE ε4 carriers might have differential therapeutic response or higher risk of treatmentrelated adverse effects. Currently no medications, to our knowledge, have been shown to delay the onset of dementia in patients with MCI. 31 However, novel and promising AD therapeutics are currently being tested in clinical trials. 2, 32 If these drugs prove to be therapeutic, there would be a viable role for biomarkers of incipient AD dementia in patients with MCI because these drugs are presumably more effective if administered early in the disease process. 2 Our findings would suggest that patients with MCI who have abnormal-CSF A␤42 might be ideal candidates for such therapies because of their comparatively elevated risk of transitioning to AD dementia. In general, because CSF biomarkers putatively reflect biochemical processes in the brain, 5, 33 it is foreseeable that they could be used for matching patients to treatment approach (eg, CSF A␤42 findings may be used to assign patients to treatments that target ␤-amyloid plaques). 33 A potential limitation of this study is the small sample size of the group of patients with MCI who have abnormal T-tau, which resulted in an inability to reliably conduct some significance tests in this study. However, we note that the findings in the p-tau 181 -A␤42 tetrad (in which the distribution of the groups was relatively more proportional) closely mirrored the findings in the T-tauA␤42 models, thus lending credibility to the observations made in the T-tauA␤42 groups. It would be of great interest to see whether this study's key finding-that abnormal A␤42 is deleterious even when tau is normal-is replicable in other well-characterized and prospectively monitored cohorts of patients with amnestic MCI. Additional Contributions: Data used in the preparation of this article were obtained from the ADNI database (http://adni.loni.ucla.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI Principal Investigators is available at http://adni.loni.ucla.edu/about/who-we-are/principal -investigators/.
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